









Markets
/
Stocks
/
nasdaq-ttnp
/

Titan Pharmaceuticals Inc

TTNP

4.310USD

+0.130+3.11%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

5.73MMarket Cap

LossP/E TTM



Titan Pharmaceuticals Inc

4.310

+0.130+3.11%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

249 / 506

Overall Ranking

407 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Undervalued

The company’s latest PE is -1.47, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 414.53K shares, decreasing 9.21% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 11.38K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.49.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.96, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.96

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.33

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.43, which is -41.11% below the recent high of -0.84 and 24.21% above the recent low of -1.08.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 249/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.80, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 5.06 and the support level at 3.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.80

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.006

Neutral

RSI(14)

48.870

Neutral

STOCH(KDJ)(9,3,3)

52.953

Neutral

ATR(14)

0.317

Low Volatility

CCI(14)

100.505

Buy

Williams %R

34.667

Buy

TRIX(12,20)

-0.278

Sell

StochRSI(14)

68.738

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

4.299

Buy

MA10

4.269

Buy

MA20

4.331

Sell

MA50

4.420

Sell

MA100

4.436

Sell

MA200

4.025

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 44.46%, representing a quarter-over-quarter increase of 4.98%. The largest institutional shareholder is James Simons, holding a total of 11.38K shares, representing 0.86% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Choong (Choon Hau)

241.53K

Chung (Jeffrey)

143.84K

Citadel Advisors LLC

11.96K

Geode Capital Management, L.L.C.

6.91K

UBS Financial Services, Inc.

2.59K

-2.74%

Ben-Tzvi (Avraham)

3.31K

The Vanguard Group, Inc.

Star Investors

4.10K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.17, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.